Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2021-10-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
瑞银证券有限责任公司关于前沿生物药业（南京）股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a securities firm regarding the unlocking and circulation of restricted shares following a company's initial public offering (IPO) on the Shanghai Stock Exchange's Sci-Tech Innovation Board (科创板). It references regulatory approvals, shareholding details, lock-up periods, and compliance with securities laws. The document is not a financial report, earnings release, or management discussion, but rather a formal regulatory compliance and verification statement related to share circulation post-IPO. It does not announce voting results, changes in management, or capital structure changes, nor is it a proxy or AGM material. Given the nature of the document as a regulatory compliance and verification opinion related to share circulation and lock-up release, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length is under 5,000 characters, but it contains substantive content rather than just a report publication announcement. Therefore, the classification is RNS with high confidence.
2021-10-20 Chinese
前沿生物独立董事关于第二届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on specific board meeting matters related to the use and management of raised funds, including opening a guarantee account and cash management of temporarily idle raised funds. It references regulatory guidelines and company articles but does not contain financial statements or detailed financial results. The document is a formal opinion related to board decisions rather than a full management report or financial report. It is not a report publication announcement or a certification letter but a governance-related document expressing independent directors' views on board matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board-related matters and decisions.
2021-10-15 Chinese
瑞银证券有限责任公司关于前沿生物药业（南京）股份有限公司通过开设募集资金保证金账户的方式开具银行承兑、保函及信用证支付募集资金投资项目款项的核查意见
Regulatory Filings Classification · 90% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of raised funds by a company (前沿生物药业) through a special escrow account for bank acceptance bills, guarantees, and letters of credit to pay for investment projects. It references regulatory approvals, fundraising amounts, investment projects, and internal approvals. The document includes detailed descriptions of the fundraising, investment projects, and the procedural and supervisory framework for using the funds. It is not a financial report like an annual or interim report, nor is it a brief announcement or a certification. It is a regulatory compliance and verification report related to fundraising and fund usage, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories such as Capital/Financing Update (CAP) or Audit Report (AR). The document length is under 5,000 characters, but it contains substantive content rather than just an announcement of a report publication, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2021-10-15 Chinese
瑞银证券有限责任公司关于前沿生物药业（南京）股份有限公司使用暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion and verification report by a sponsoring securities company regarding the use of temporarily idle raised funds by a listed company for cash management. It references regulatory guidelines, fundraising details, investment projects, and internal approvals. The document does not contain financial statements or quarterly/yearly financial results but focuses on the management and regulatory compliance of the use of raised funds. It is not an announcement of a report but a formal verification opinion related to fundraising and cash management. This fits best under the category of Regulatory Filings (RNS), as it is a compliance and regulatory disclosure document that does not fit into other specific categories like Annual Report, Interim Report, or Capital/Financing Update.
2021-10-15 Chinese
前沿生物关于使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory approvals, investment purpose, risk control measures, and compliance with regulatory requirements. It does not contain financial statements or detailed financial results but rather describes a financing-related operational update. The document length is 4692 characters, which is relatively short and focused on a specific financing/cash management activity. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP.
2021-10-15 Chinese
前沿生物关于通过开设募集资金保证金账户的方式开具银行承兑、保函及信用证支付募集资金投资项目的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the approval and procedural details of using a special escrow account for handling funds raised through a public stock issuance. It discusses the use of raised funds, approvals by the board and supervisory committee, independent director opinions, and sponsor institution verification. The document does not contain financial statements or detailed financial results but rather focuses on the management and use of capital raised and related procedural approvals. It is not a full financial report, earnings release, or audit report. It is also not a simple announcement of a report publication but a substantive regulatory announcement about capital management. This fits best under Capital/Financing Update (CAP) as it relates to the use and management of fundraising proceeds and capital structure.
2021-10-15 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.